News from Zyme and the companies we work with.

February 13, 20

Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics

Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant Pico-Surf offers reliable, highly stable and high-quality droplet generation and processing for microfluidic applications Cambridge, UK, 13 February 2020: Sphere Fluidics, a company commercializing single cell analysis … Continue reading →

February 12, 20

The Native Antigen Company Introduces Novel Coronavirus Antigens

Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development Oxford, UK, 12 February 2020: The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into … Continue reading →

February 11, 20

ERS Genomics and Aelian Biotechnology announce CRISPR/Cas9 license agreement enabling Aelian’s unique screening platform

DUBLIN, Ireland, and VIENNA, Austria, 11 February 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Aelian Biotechnology (“Aelian”) today announced the signing of a license … Continue reading →

February 10, 20

ERS Genomics provides comment on affirmation of key CRISPR-Cas9 patent involved in European opposition proceedings  

DUBLIN, Ireland, 10 February 2020 – ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier, announced today that the European Patent Office (EPO) has rejected arguments filed in … Continue reading →

February 10, 20

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies … Continue reading →

February 5, 20

ELRIG UK and British Pharmacological Society appoint Dr Ann Hayes to chair joint steering committee

Renowned drug discovery leader to guide alliance formed to improve scientific exchange in UK drug discovery community York and London, UK, 5 February 2020: The European Laboratory Research & Innovation Group (ELRIG) UK and the British Pharmacological Society, today announced … Continue reading →

February 5, 20

Start Codon joins Cancer Research UK’s Entrepreneurial Programmes Initiative

Aims to support the next generation of oncology-based start-ups Start Codon to focus on Cambridge, UK, research community, supporting new businesses that will address unmet medical needs CAMBRIDGE and LONDON, UK, 05 February 2020 – Start Codon, a new model … Continue reading →

February 4, 20

The Native Antigen Company Introduces Antigen and Antibody Conjugation Kits

Highly scalable kits enable researchers to prepare liquid-stable antigen and antibody conjugates with a wide range of labels including enzymes, fluorochromes, and biotin Oxford, UK, 4 February 2020: The Native Antigen Company, one of the world’s leading suppliers of reagents … Continue reading →

February 3, 20

Lab of the Future Congress USA, 19–20th May 2020, Boston MA

USA congress showcasing research innovation in the life sciences Follows successful European event in Cambridge, UK Cambridge, UK, and Boston, MA, USA, 03 February 2020: Open Pharma Research, a platform for information exchange and networking in the life sciences, today … Continue reading →

February 3, 20

PhoreMost strengthens leadership team with two key appointments

Dr Catherine Beech, OBE, joins Board as a Non-Executive Director Dr Benedict Cross joins as Senior Director (Technology) Cambridge, UK, 03 February 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has made … Continue reading →